Cart
sales@molnova.com
Daclizumab
CAS No. 152923-56-3
Daclizumab( —— )
Catalog No. M36558 CAS No. 152923-56-3
Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 324 | Get Quote |
|
| 5MG | 511 | Get Quote |
|
| 10MG | 820 | Get Quote |
|
| 25MG | 1187 | Get Quote |
|
| 50MG | 1619 | Get Quote |
|
| 100MG | 2142 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDaclizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionDaclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA.
-
DescriptionDaclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number152923-56-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Stanley L Cohan, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18.?
molnova catalog
related products
-
Canakinumab
Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively.
-
Chrysosplenol D
Chrysosplenol D, an efflux pump inhibitor that can potentiate the activity of commercially important antibiotics and antimalarials.
-
Apilimod 2HCl
Apilimod 2HCl (STA 5326 2HCl) is a PIKFYVE kinase inhibitor that promotes NLRP3 inflammatory vesicle activation, IL-1β secretion, and cellular pyroptosis, and is used in the study of amyotrophic lateral sclerosis.
